Insider trades
Gwenn Hansen, Chief Officer of Nurix Therapeutics NRIX, has filed 0 purchases and 17 sales on the open market. Over the past 12 months that comes to a net sale of $294.9K. The latest trade was on 06/25.
Gwenn Hansen
Chief Scientific Officer
- Company
- Nurix Therapeutics NRIX
- First filing
- 23/02/01
- Trades
- 102 trades
- Buys / sales
- 0 / 17
- 12-month net buying
- −$294.9K
- Last trade
- 06/25
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale10b5-1 plan | 06/25 | 06/25 | 5,394 sh | $20.00 | $107,880 | −4.5% | |
| Open-market sale | 04/30 | 04/30 | 3,214 sh | $16.65 | $53,513.1 | −2.6% | |
NRIX | Open-market sale | 01/30 | 01/30 | 4,895 sh2 trades | $16.60avg. | $81,236.52 | −5.5% |
| Open-market sale | 25/10/30 | 25/10/30 | 4,087 sh | $12.80 | $52,313.6 | −5.1% | |
| Open-market sale | 25/07/30 | 25/07/30 | 4,308 sh | $12.01 | $51,739.08 | −5.9% | |
| Open-market sale | 25/04/30 | 25/04/30 | 3,377 sh | $11.50 | $38,835.5 | −5.2% | |
NRIX | Open-market sale | 25/01/30 | 25/01/30 | 3,690 sh2 trades | $19.86avg. | $73,272.06 | −6.2% |
| Open-market sale | 24/10/30 | 24/10/30 | 3,437 sh | $24.31 | $83,553.47 | −6.4% | |
| Open-market sale | 24/07/30 | 24/07/30 | 3,408 sh | $20.67 | $70,443.36 | −7.0% | |
| Open-market sale | 24/04/30 | 24/04/30 | 2,007 sh | $12.04 | $24,164.28 | −4.8% | |
| Open-market sale | 24/01/30 | 24/01/30 | 2,334 sh | $7.99 | $18,648.66 | −6.0% | |
| Open-market sale | 23/10/31 | 23/11/01 | 1,633 sh | $5.20 | $8,491.6 | −4.6% | |
| Open-market sale | 23/07/31 | 23/08/01 | 1,884 sh | $9.65 | $18,180.6 | −5.9% | |
| Open-market sale | 23/05/01 | 23/05/02 | 1,136 sh | $9.88 | $11,223.68 | −4.1% | |
| Open-market sale | 23/01/30 | 23/02/01 | 1,412 sh | $11.78 | $16,633.36 | −5.8% |